Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study

Publisher： Karger

E-ISSN： 1423-0232|77|6|395-399

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.6, 2010-02, pp. : 395-399

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3020-3026

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intraperitoneal chemotherapy of ovarian cancer

By Lowe Thomas   Morgan Robert J  

Women's Health, Vol. 3, Iss. 4, 2007-07 ,pp. : 433-440

Future Medicine

Access to resources Recommend Favorite

The Role of Neoadjuvant Chemotherapy in the Treatment of Advanced Ovarian Cancer

By  

Oncology, Vol. 68, Iss. 1, 2005-04 ,pp. : 64-70

Karger

Access to resources Recommend Favorite

Excision repair cross‐complementation group 1 protein expression predicts survival in patients with high‐grade, non‐metastatic osteosarcoma treated with neoadjuvant chemotherapy

By  

HISTOPATHOLOGY, Vol. 67, Iss. 3, 2015-09 ,pp. : 338-347

John Wiley & Sons Inc

Access to resources Recommend Favorite

Neoadjuvant chemotherapy in bladder cancer

By Tully Christopher M   Iyer Gopa   F Bajorin Dean  

Clinical Investigation, Vol. 3, Iss. 10, 2013-10 ,pp. : 991-1002

Future Science

Access to resources Recommend Favorite